Citius Oncology, Inc. (CTOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($35.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Citius Oncology, Inc. (CTOR) market capitalisation for the company's overall valuation and market capitalisation.
Citius Oncology, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency. Explore CTOR operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nature and Environment Co. Ltd
KQ:043910
|
0.031x |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
-0.011x |
|
Viatron Technologies Inc
KQ:141000
|
0.050x |
|
Great Elm Capital Corp
NASDAQ:GECC
|
0.119x |
|
Yao Sheng Electronic Co Ltd
TWO:3207
|
0.005x |
|
Hannan Metals Ltd
V:HAN
|
-0.019x |
|
Kelly Services B Inc
NASDAQ:KELYB
|
0.050x |
|
KEYEAST.Co.Ltd
KQ:054780
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. View Citius Oncology, Inc. stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary… Read more